Predictive Oncology, Every Cure announce strategic collaboration

Predictive Oncology (POAI) and Every Cure announced a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes and save lives. Predictive Oncology has a longstanding commitment to supporting the best treatments for patients diagnosed with cancer, through both proprietary clinical assays and AI-driven machine learning. These capabilities allow for the rapid screening of a drug against a broad range of tumor types, with the goal of predicting a patient’s response to an anti-cancer therapy. “This collaboration on drug repurposing leverages our unique assets and capabilities, most notably our vast biobank of more than 150,000 tumor samples across more than 130 different cancer types,” said Raymond Vennare, CEO of Predictive Oncology. “Together we believe we can make a meaningful difference in the lives of patients in need, and we are pleased to be able to assist Every Cure in advancing these efforts”